Related Experiment Video
Updated: Mar 27, 2026
10:28
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
11.7K
Prognostic value of negative interim 2-[¹⁸F]-fluoro-2-deoxy-d-glucose PET/CT in diffuse large B-cell lymphoma
1Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Suwon, South Korea.
Clinical Radiology
|January 7, 2016
Summary
A negative interim 2-[(18)F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) scan does not guarantee remission in diffuse large B-cell lymphoma (DLBCL). Close follow-up is crucial, particularly for patients with a high International Prognostic Index score.
Area of Science:
- Nuclear medicine imaging
- Oncology
- Hematology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
- Early assessment of treatment response is critical for guiding therapy and predicting outcomes.
Purpose of the Study:
- To evaluate the prognostic significance of a negative interim 2-[(18)F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) scan in DLBCL patients treated with R-CHOP chemotherapy.
- To identify factors that predict treatment failure despite a negative interim scan.
Main Methods:
- Ninety-two DLBCL patients underwent baseline and interim (after 2 R-CHOP cycles) (18)F-FDG PET/CT scans.
- Interim PET/CT was assessed visually for abnormal (18)F-FDG uptake.
- Progression-free survival (PFS) was analyzed using Cox proportional hazards models, considering clinicopathological and imaging parameters.
Main Results:
- 39.1% of patients experienced lymphoma progression during a median follow-up of 30.8 months.
- Univariate analysis identified Ann Arbor stage, LDH, ECOG, IPI score, and initial SUVmax as significant prognostic factors for PFS.
- The International Prognostic Index (IPI) score (≥3) was the only independent predictor of poorer PFS (p=0.044).
Conclusions:
- A negative interim (18)F-FDG PET/CT scan in DLBCL patients does not exclude the possibility of disease progression.
- Close patient monitoring is essential, especially for individuals with a high IPI score, even after achieving a negative interim scan.
- The findings underscore the need for continued vigilance in DLBCL management.
